AUTHOR=Stevens Claire , Hightower Alexandria , Buxbaum Sarah G. , Falzarano Sara M. , Rhie Suhn K. 

TITLE=Genomic, epigenomic, and transcriptomic signatures of prostate cancer between African American and European American patients

JOURNAL=Frontiers in Oncology

VOLUME=13

YEAR=2023

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2023.1079037

DOI=10.3389/fonc.2023.1079037

ISSN=2234-943X

ABSTRACT=<p>Prostate cancer is the second most common cancer in men in the United States, and racial disparities are greatly observed in the disease. Specifically, African American (AA) patients have 60% higher incidence and mortality rates, in addition to higher grade and stage prostate tumors, than European American (EA) patients. In order to narrow the gap between clinical outcomes for these two populations, genetic and molecular signatures contributing to this disparity have been characterized. Over the past decade, profiles of prostate tumor samples from different ethnic groups have been developed using molecular and functional assays coupled with next generation sequencing or microarrays. Comparative genome-wide analyses of genomic, epigenomic, and transcriptomic profiles from prostate tumor samples have uncovered potential race-specific mutations, copy number alterations, DNA methylation, and gene expression patterns. In this study, we reviewed over 20 published studies that examined the aforementioned molecular contributions to racial disparities in AA and EA prostate cancer patients. The reviewed genomic studies revealed mutations, deletions, amplifications, duplications, or fusion genes differentially enriched in AA patients relative to EA patients. Commonly reported genomic alterations included mutations or copy number alterations of <italic>FOXA1, KMT2D, SPOP, MYC</italic>, <italic>PTEN</italic>, <italic>TP53</italic>, <italic>ZFHX3</italic>, and the <italic>TMPRSS2</italic>-<italic>ERG</italic> fusion. The reviewed epigenomic studies identified that CpG sites near the promoters of <italic>PMEPA1</italic>, <italic>RARB</italic>, <italic>SNRPN</italic>, and <italic>TIMP3</italic> genes were differentially methylated between AA and EA patients. Lastly, the reviewed transcriptomic studies identified genes (e.g. <italic>CCL4, CHRM3</italic>, <italic>CRYBB2</italic>, <italic>CXCR4, GALR1</italic>, <italic>GSTM3</italic>, <italic>SPINK1</italic>) and signaling pathways dysregulated between AA and EA patients. The most frequently found dysregulated pathways were involved in immune and inflammatory responses and neuroactive ligand signaling. Overall, we observed that the genomic, epigenomic, and transcriptomic alterations evaluated between AA and EA prostate cancer patients varied between studies, highlighting the impact of using different methods and sample sizes. The reported genomic, epigenomic, and transcriptomic alterations do not only uncover molecular mechanisms of tumorigenesis but also provide researchers and clinicians valuable resources to identify novel biomarkers and treatment modalities to improve the disparity of clinical outcomes between AA and EA patients.</p>